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Apstrakt
Background. Recently, a growing number of case reports
and case series have suggested that the use of recombinant
activated factor VII (rFVIIa) may be effective in treatment
of patients with non-hemophilic acquired coagulopathy not
responding to conventional treatment such as major sur-
gery, major trauma, sepsis, necrotizing pancreatitis and
bleeding due to cerebral arteriovenous malformations. Case
report. We presented a septic patient with massive, life-
threatening bleeding caused by retroperitoneal necrosis, due
to severe acute necrotizing pancreatitis. As conservative
treatment (blood, plasma, cryoprecipitates and platelet
transfusions) failed to induce cessation of bleeding, the pa-
tient was urgently operated on. In spite of usual procedures
of surgical hemostasis (ligation, suture, thermocauterisation,
fibrin glue, temporary tamponade), hemorrhage could not
be stopped. The patient manifested the signs of hypother-
mia and metabolic acidosis and, therefore, the decision was
made to use recombinant activated factor VII (Novo
Seven®). The application of rFVIIa resulted in significant
discontinuation of hemorrhage, restoration to normal blood
count as well as other relevant coagulation parameters.
Conclusion. Although application of rFVIIa is still in the
initial clinical phase, and the experience is based mainly on
uncontrolled series as well as on individual observations, it
seems that this drug can be promising, potent and attractive
adjunctive prohemostatic agent. This drug may play a bene-
ficial role in the treatment of serious and unresponsive,
“nonsurgical”, life-threatening bleeding due to severe acute
necrotizing pancreatitis.
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Abstract
Uvod. U poslednje vreme sve veći broj prikaza i serija
bolesnika ukazuje da primena rekombinantnog aktiviranog
faktora VII (rFVIIa) može biti efikasna u lečenju bolesnika
sa koagulopatijom nehemofiličnog porekla, neosetljivom
na konvencionalno lečenje, kao što su hirurgija, trauma,
sepsa, nekrotični pankreatitis i krvarenje usled cerebroarte-
riovenskih nepravilnosti. Prikaz bolesnika. Predstavili
smo bolesnika sa sepsom i masivnim krvarenjem opasnim
po život, izazvanim retroperitoneumskom nekrozom zbog
teškog akutnog nekrotičnog pankreatitisa. Pošto nije bilo
moguće zaustaviti krvarenje primenom konzervativnog le-
čenja, bolesnik je hitno operisan. Uprkos uobičajenim pro-
cedurama hirurške hemostaze (ligatura, sutura, termokau-
terizacija, fibrinski lepak, privremena tamponada) hemora-
giju nije bilo moguće zaustaviti. Bolesnik je pokazivao
znakove hipotermije i metaboličke acidoze, te je odlučeno
da se primeni rekombinantni aktivirani faktor VII (Novo
Seven®). Primena ovog faktora imala je za rezultat znača-
jan prekid hemoragije, uspostavljanje normalnog broja cr-
venih krvnih zrnaca, kao i drugih važnih parametara koa-
gulacije. Zaključak. Iako je primena rekombinantnog fa-
ktora VIIa još uvek u početnoj kliničkoj fazi, a iskustvo
uglavnom zasnovano na nekontrolisanim serijama i indivi-
dualnim zapažanjima, izgleda da ovaj lek obećava i da je
moćan i atraktivan pomoćni prohemostatski preparat. Lek
može imati pozitivnu ulogu u lečenju teškog i nereaguju-
ćeg ,,nehirurškog“, životnougrožavajućeg krvarenja usled
ozbiljnog nekrotičnog pankreatitisa.
Ključne reči:
faktor VIIa; krvarenje; retroperitonealni prostor;
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Introduction
It is well known that one of the most widespread compli-
cations of severe acute pancreatitis is sepsis caused by activa-
tion of proinflammatory cascade of mediators and followed by
subsequent bacterial infection 
1. Among many systemic com-
plications of sepsis due to severe acute pancreatitis is sepsis-
induced coagulopathy. Moreover, infected necrosis of the pan-
creas, peripancreatic and retroperitoneal tissue, may cause di-
rect erosion of blood vessels, bringing about the risk of mas-
sive, often uncontrollable, unresponsive, even fatal bleeding.
Standard therapy for achieving hemostasis in these
bleeding cases involves supplementation of blood and blood
derivatives. If hemorrhage does not cease, such conservative
treatment may further compromise coagulation, introducing
patient to dilutional coagulopathy, or other posttransfusion
complications. In life-threatening bleeding cases, emergency
laparotomy is necessary, but an attempt of surgical hemosta-
sis is rather limited and often unsuccessful.
Recently, a growing number of case reports and case
series have suggested that the use of recombinant activated
factor VII (rFVIIa) may be effective in treatment of patients
with non-hemophilic acquired coagulopathy, who do not re-
spond to conventional treatment such as major surgery, ma-
jor trauma, sepsis, necrotizing pancreatitis and bleeding due
to cerebral arteriovenous malformations
 2–7.
We reported a patient with severe acute necrotizing
pancreatitis, complicated with sepsis who had life-threating
retroperitoneal bleeding irresponsive to standard blood prod-
ucts supplementation and surgical treatment, successefully
treated with human recombinant activated factor VII (Novo
Seven
®; Novo Nordisk, Bagsvaerd, Denmark).
Case report
A male patient, 55 years of age, was admitted to our in-
stitution with a two-week history of gallstone-induced acute
pancreatitis and with no preexisting coagulopathy. Contrast
computerized tomography (CCT) performed on day 6 from
the admission verified the presence of necrotic zones in the
pancreas (over 50%) and peripancreatic tissue, with tendency
to expand towards the left retroperitoneal space. As the pa-
tient had no clinical or laboratory signs of generalized infec-
tion and sepsis, intensive conservative treatment was initi-
ated immediately. In addition, prophylactic antibiotic therapy
was applied, while three-lumen nasojejunal tube was inserted
for enteral nutritive support.
On day 15 of his stay, the abdominal pain followed by ab-
dominal distension (abdominal compartment) was noticed,
while body temperature was increased abruptly (39º C). White
blood count (18 × 10
9/L) and C-reactive protein (380 mg/L) lev-
els were increased along with aggravation of general condition.
Percutaneous ultrasound-guided fine needle biopsy was per-
formed and lavate was sent to microbiological identification.
Two days later, Klebsiella and E. coli were discovered from the
culture, and such evidence of infected necrosis called for imme-
diate laparotomy. During the surgery, a large volume of ascites
was evacuated while peripancreatic necrotic tissue was re-
moved, followed by lavage and drainage. Since a further pro-
gression of necrotic process could be expected, the decision was
made not to carry out primary closure of the abdomen but to use
zipper technique (Ethy-Zipp®) and to perform planned relapa-
rotomies with successive staged abdominal lavages and addi-
tional necrosectomies. In the following 35 days, 7 additional
staged lavages with necrosectomies were carried out. After day
35, the abdomen was definitely closed, and drains were placed
in retroperitoneum for a continuous lavage. During relaparoto-
mies and staged necrosectomies followed with lavages, local
findings and general condition of the patient gradually im-
proved. Since respiratory insufficiency was persistent, the pa-
tient was supported by assist ventilation all the time.
On day 55 of the stay, a sudden and fulminant abdomi-
nal hemorrhage occurred, which was manifested by a large
amount of warm blood in surgical wound and abdominal
drains. The initial blood loss was estimated to approximately
2 liters. Immediate relaparotomy was performed. Upon the
abdomen exposure, besides enlarged, septically altered
spleen with signs of incipient spontaneous rupture, diffuse
bleeding from retroperitoneal space was noted. Splenectomy
was carried out, but in spite of the attempts of surgical hemo-
stasis, retroperitoneal hemorrhage could not be stopped.
Tamponade of retroperitoneal space as the source of bleeding
was performed and the abdomen closed temporary.
In spite of massive supplementation of blood and blood
derivatives administered during the surgery and in an early
(24 hours) postoperative period, (9 160 mL of whole blood –
25 units, 7 625 mL of fresh frozen human plasma – FFP – 38
units, 825 mL of cryoprecipitate – 30 units and 600 mL of
platelets – 10 units), the patient kept on bleeding, with mean
blood loss rate of about 130 mL/min. The patient manifested
a picture of a severe hemorrhagic shock with hypothermia
(35.8° C) and metabolic acidosis. Due to prominent hypoten-
sion and imminent cardiocirculatory collapse, inotropic sup-
port was initiated (adrenaline and dopamine).
At last, a desperate decision was made to use recombi-
nant activated factor VII (Novo Seven
®), and rFVIIa was ap-
plied in a dose of 120 μg/kg in iv bolus lasting 5 minutes.
Two hours after application of the first dose of rFVIIa, the
hemorrhage was drastically reduced. After 24 hours the same
dose of Novo Seven
® was repeated. Supplementation of
blood and blood derivatives was continued for the next few
days, and five days later a hemogram became completely
normal, while hemorrhage definitely stopped (Table 1).
In spite of excessive replacement of blood and blood
derivates during a 48-hour period no signs of acute respira-
tory distress syndrome were manifested in the postoperative
period. Moreover, no side-effects were noted following the
application of recombinant factor VIIa in view of systemic
thromboembolism, i.e. there was no laboratory or clinical
confirmation of systemic thrombotic sequelae.
On day 70, the signs of candidal pulmonary infection
were evident. In spite of repetitive and aggressive antimy-
cotic therapy (fluconazole, amphotericin B), it failed to yield
positive therapeutic effects. Therefore, on day 109 from hos-
pitalization, lethal outcome with all signs of general Can-
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Discussion
Operated patients with acute severe necrotizing pan-
creatitis may suffer from profound bleeding due to retro-
peritoneal necrosis, accompanied by sepsis-induced coagu-
lopathy 
8. The standard treatment of such bleeding is an
early, vigorous and aggressive replacement therapy by ad-
ministration of blood products, but it promotes a risk of fur-
ther dilutional coagulopathy, massive transfusion syndrome,
and other possible posttransfusion complications 
9. Attempts
of surgical hemostasis in these uncontrollable bleeding pa-
tients, such as ligation, suture, cauterization, temporary
packing (tamponade), use of fibrin glue, or even argon beam
laser, are often ineffective.
Such failure to control a source of bleeding often leads
to consumption coagulopathy. An additional mechanism al-
tering the process of clot formation is an activation of fibri-
nolytic system, excessive fibrinolysis and subsequent dis-
ruption of newly formed clots, which all make patient to be
caught into a vicious cycle. Contributing effects of additional
hypothermia and metabolic acidosis have negative impact on
clotting process in view of further refractory coagulopathy,
hypoperfusion and irreversible cellular shock
 10.
Recombinant activated factor VII (rFVIIa) was intro-
duced in clinical medicine more than 10 years ago and li-
censed as prohemostatic agent for the treatment of hemo-
philic patients with inhibitors for over 5 years
 11. Recombi-
nant activated factor VIIa is a 50 kDa analog of the naturally
occurring serine protese
 12. Circulating half-life of rFVIIa is
2.7 hours
 11. Recombinant activated factor VII increases local
thrombin generation at sites where the endothelium is dam-
aged, resulting in an increased platelet activation and aggre-
gation and enhancing fibrin deposition
 13. Recombinant acti-
vated factor VIIa also decreases the lag-time of clot forma-
tion
 14. Final result of such rFVIIa action is stable, insoluble
fibrin “superclot”, which has stronger architecture and is
much more resistant to degradation by fibrinolytic enzymes
compared with normal clot
 15.
There has been still considerable disagreement on the
mechanism of action of rFVIIa, so its mode of action has not
been established yet. According to current knowledge the
mode of action of recombinant factor VIIa might be based on
two possible alternative mechanisms.
The first mechanism, supported by Mann et al. 
16 is de-
pendent upon and mediated by the tissue-factor pathway.
Recombinant activated factor VIIa becomes active after
forming a complex with tissue factor (TF), which is released
from subendothelial media of damaged vessel wall. This
complex (rFVIIa-TF) initiates the activation of coagulation
cascade by the extrinsic pathway, activating factors X and IX
– just at the site of the vessel injury, and without triggering
the systemic activation of blood coagulation. In that way,
rFVIIa makes "bypass", avoiding and eliminating systemic
coagulation effects
 4, 13.
Another mechanism of action of rFVIIa revised the
classical concept of coagulation cascade. This is a cell-based
model, designed on the theory about dominating cell mem-
brane role. A cell-based model emphasizes the importance of
specific cell receptors for coagulation proteins and states that
hemostasis takes place on two cell surfaces: TF bearing cells
and activated platelet membranes
 17. According to this hy-
pothesis, rFVIIa initiates coagulation in the absence of tis-
sue-factor pathway. Triggering a direct activation of factor
X, rFVIIa leads to acceleration and amplification of throm-
bin generation on the surface of phospholipid membrane of
activated platelets, adhering at the site of the injury. Final re-
sult of this action is a subsequent formation of fibrin
clot
 4, 14, 17, 18.
According to the aforementioned, rFVIIa has two po-
tential and possible sites of action in surgery and trauma: at
injury site, where rFVIIa binds to tissue factor (TF), previ-
ously released from the injured vessel, and on the surface of
Table 1
Values of coagulation parameters during epizodes of bleeding
Day of
bleeding BT°C RBC
(× 10
12/L)
Hg
(g/L)
Htc
(l/L)
Plt
(× 10
9/L)
PT
(s) PTT (s) INR D-dimer
μg/L
AT3
(%)
Fibrinogen
(g/L)
Day before
bleeding 37.2 3.16 96 0.28 204 18.7 39.4 1.57 225 64 2,6
1th day
of bleeding 35.8 1.61 48 0.14 59 21.4 38.4 1.80 351 45 2
2nd day of
bleeding
(1th day of
NovoSeven)
36.3 2.84 88 0.25 70 12.4 34.4 1.04 291 62 3.2
3rd day (after)
bleeding
(2nd day of
NovoSeven)
36.9 2.99 93 0.27 68 13.4 36.5 1.13 242 56 3.4
4th day (after)
bleeding 37.0 3.18 100 0.29 96 9.8 30.7 0.82 231 62 3.7
5th day (after)
bleeding 37.1 3.02 93 0.27 147 13.6 33.1 1.14 250 62 3.1
Normal range
values 11.5 25–42 < 250 80–120 1.8–3.5
BT – body temperature; RBC – red blood cell count; Hg – hemoglobin serum value; Htc – hematocrit; Plt – platelets number; PT – protrombin time;
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activated platelets, producing thrombin, independently of
TF
 4.
The only requirement for a sufficient activity of rFVIIa
is enough quantity of platelets (> 50 × l0
9/L) and enough
quantity of fibrinogen (> 50 mg/dL). According to the expe-
rience so far, rFVIIa activity has not been reduced by
hipothermia. The only limiting factor lowering the effect of
rFVIIa is metabolic acidosis
 19.
Whatever it generally does, rFVIIa markedly stopped
the fulminant hemorrhage in our patient with severe acute
necrotizing pancreatitis. It was clear that initially ruptured
septic spleen was not the primary source of bleeding, but dif-
fuse altered peripancreatic and retroperitoneal veins were the
main origin of hemorrhage. The cessation of bleeding did not
occur immediately, but slowly, during the following 24 hours
from the start of rFVIIa administration. The parameters of
coagulation cascade also restored to normal during the next
several days and the patient recovered coagulation status.
After that time, the patient was alive during the following
two months. His death was not related to bleeding, but
caused by candidal sepsis.
An optimal dose of rFVIIa and timing of rFVIIa ad-
ministration have not been determined yet. Although dosage
depends on prophylactic or therapeutical use and varies in
range from 20 μg/kg to “megadose” of over 300 μg/kg, the
majority of authors advocate, suggest and recommend a dose
between 90–120 μg/kg 
18.
According to the majority of reports, timing of rFVIIa
administration in uncontrollable life-threatening bleeding
patients with a high rate of blood loss followed by unsuc-
cessful and ineffective attempts of surgical hemostasis is – as
soon as possible, before manifestation of hypothermia and
metabolic acidosis, and before noticeable signs of irreversi-
ble hemorrhagic shock.
The cost-benefit of rFVIIa use is actually not known.
Despite relatively expensive cost of its use, significantly de-
creased number of transfusion units of the whole blood and
blood-derivatives, shortened stay in the intensive care unit,
reduction of transfusion – related morbidity and bleeding –
related mortality, as well as generally improved survival of
patients treated with rFVIIa, indicate that this drug may be
quite acceptable and convenient adjunctive prohemostatic
agent
 9.
Conclusion
We reported a septic patient with unresponsive retro-
peritoneal bleeding caused by severe acute necrotizing pan-
creatitis, successfully treated with recombinant activated
factor VII (Novo Seven
®; Novo Nordisk; Bagsvaerd; Den-
mark).
Although application of recombinant factor VIIa is still
in the initial clinical phase, and the experience is based
mainly on uncontrolled series as well as on individual obser-
vations, it seems that this drug can be promising, potent and
attractive adjunctive prohemostatic agent. Although our re-
port offers limited insight into the subject, it could contribute
to the establishment of some selection criteria for clinical use
of rFVIIa. This drug may play a beneficial role in the treat-
ment of serious and unresponsive, “non surgical”, life –
threatening bleeding due to severe acute necrotizing pan-
creatitis, as well as units transfused along with their compli-
cations and cut down total expenses.
Despite the fact that these results seem promising and
encouraging, randomized multicentric clinical trials are nec-
essary to confirm such initial observations.
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